Financial Data and Key Metrics Changes - Net revenue for the quarter was $15.2 million, down from $16.2 million in the prior year [20] - ADHD portfolio net revenue was $13.2 million, compared to $13.8 million in the prior year, remaining flat with the previous quarter [20] - Pediatric portfolio revenue increased to $1.7 million from $715,000 in the previous quarter, but down from $2.7 million in the prior year [18][21] - Gross margin decreased to 63.5% from 66.5% year-over-year, primarily due to decreased net revenue and transition-related expenses [22] - The company reported a net loss of $10.6 million, compared to a net income of $0.8 million in the prior year [23] Business Line Data and Key Metrics Changes - The ADHD portfolio is experiencing a slight decrease in revenue due to a shift in marketing focus towards EXXUA and the introduction of generic competition [16][20] - The launch of an authorized generic for Adzenys has limited the impact of Teva's generic competition, with the authorized generic representing just under 20% of total prescriptions [17] - The pediatric portfolio saw a revenue increase due to reduced returns and stabilization of prescriptions, although it remains a non-core focus for the company [18] Market Data and Key Metrics Changes - The early feedback from patients on EXXUA has been positive, with reports of good tolerability and satisfaction [15] - Prescriptions for EXXUA have been written in 27 states, indicating broad market opportunity [14] - The majority of prescriptions are being filled through the RxConnect platform, with a favorable mix towards commercial insurance [48] Company Strategy and Development Direction - The company has launched EXXUA, the first FDA-approved 5-HT1A agonist for major depressive disorder, with a comprehensive commercial launch strategy focused on prescriber adoption and brand growth [4][31] - The marketing strategy includes a mix of personal and non-personal approaches, targeting high-volume antidepressant prescribers [11] - The company plans to maintain a focus on operational efficiency while scaling its promotional investments in line with performance [14][29] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the significant unmet need in the treatment of major depressive disorder, with 50%-60% of patients failing to achieve remission on current therapies [8][9] - The company expects to see a small initial ramp in EXXUA net revenue as it removes early access barriers and guarantees coverage for patients [26][27] - Management is optimistic about the early momentum of EXXUA and the potential for long-term growth, emphasizing the importance of cash flow for future expansion [39][40] Other Important Information - The company incurred a one-time FDA PDUFA fee of $400,000 during the quarter [23] - Adjusted EBITDA was -$0.8 million for the quarter, reflecting increased launch investments and a shift in marketing focus [25] - Cash and cash equivalents were $30 million at the end of the quarter, down from $32.6 million at the end of the previous quarter [25] Q&A Session Summary Question: Feedback from doctors on EXXUA prescriptions - Management noted mixed motivations for physicians to prescribe EXXUA, including interest in its mechanism of action and ease of prescribing through RxConnect [33][34][36] Question: Plans for sales force expansion - Management indicated that expansion would be unlikely in fiscal 2026 without sufficient cash flow and profitability to support it [38][39] Question: Direct-to-consumer campaign details - The campaign will focus on web-based strategies, including search engine optimization and social media, while maintaining compliance with FDA regulations [40][41] Question: Impact of weather on prescriptions - Management confirmed that recent weather events had a significant impact on prescriptions being filled and shipments to pharmacies, but supply issues have been resolved [46][53] Question: Supply ramp-up capabilities - Management assured that adequate supply is available to meet demand, with no issues anticipated in scaling production [53][54]